KRAS and neoplasm: Although the strategy of using KRAS mutations in ctDNA as a tumor marker may be theoretically optimal in a disease like PDAC where KRAS mutation rates exceed 90%, the stochastic nature of circulating ctDNAs may lead to underestimation of the true circulating tumor burden or nature if detection is limited to a single mutation [9].